Vol. 1 No. 9 (2025), Articles
Vol. 1 No. 9 (2025)

POLYCYSTIC OVARY SYNDROME (PCOS): ENDOCRINE BASIS AND TREATMENT STRATEGIES

Articles
Published 2025-09-23
Barnoxonim Yuldasheva
Alfraganus University, Faculty of Medicine 4th-year Medical Student, Clinical Internship
Rahmatullayeva Aziza Farxodovna
Scientific Advisor: Gynecologist, Pediatric Gynecologist
PDF

Keywords

Polycystic Ovary Syndrome, PCOS, endocrine dysfunction, hyperandrogenism, insulin resistance, reproductive health, ovulatory dysfunction, metabolic risk, treatment strategies

Abstract

Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. The syndrome involves complex interactions between the hypothalamic-pituitary-ovarian axis, insulin resistance, and metabolic dysregulation. PCOS is associated with reproductive complications such as infertility, menstrual irregularities, and increased risk of pregnancy-related complications, as well as long-term metabolic and cardiovascular risks. This article reviews the endocrine mechanisms underlying PCOS and explores current therapeutic strategies, including lifestyle interventions, pharmacological treatments, and assisted reproductive technologies, emphasizing individualized care to optimize reproductive and metabolic outcomes.

PDF

References

1. Azziz, R., Carmina, E., Dewailly, D., et al. (2009). The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility, 91(2), 456–488.

2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81(1), 19–25.

3. Teede, H. J., Misso, M. L., Costello, M. F., et al. (2018). International PCOS Guideline: 2018 update. Human Reproduction, 33(9), 1602–1618.

4. Moran, L. J., Misso, M. L., Wild, R. A., Norman, R. J. (2010). Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 16(4), 347–363.

5. Legro, R. S., Arslanian, S. A., Ehrmann, D. A., et al. (2013). Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 98(12), 4565–4592.

6. Diamanti-Kandarakis, E., Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews, 33(6), 981–1030.

7. Palomba, S., Falbo, A., Zullo, F., Orio, F. (2015). Evidence-based and potential benefits of metformin in women with polycystic ovary syndrome. Endocrine, 48(2), 295–306.

8. Fauser, B. C., Tarlatzis, B. C., Rebar, R. W., et al. (2012). Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. Human Reproduction, 27(1), 14–24.

9. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81(1), 19–25.

10. Nestler, J. E., Jakubowicz, D. J. (2001). Lean women with polycystic ovary syndrome respond to insulin reduction with metformin. Diabetes Care, 24(4), 619–622.